LPL Financial LLC Has $5.86 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

LPL Financial LLC trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 14.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,070 shares of the medical research company’s stock after selling 6,872 shares during the quarter. LPL Financial LLC owned 0.08% of Charles River Laboratories International worth $5,858,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Two Sigma Securities LLC grew its holdings in shares of Charles River Laboratories International by 4.3% during the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company’s stock worth $366,000 after purchasing an additional 81 shares in the last quarter. Wahed Invest LLC grew its holdings in shares of Charles River Laboratories International by 6.5% during the 4th quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company’s stock worth $244,000 after purchasing an additional 81 shares in the last quarter. Teachers Retirement System of The State of Kentucky grew its holdings in shares of Charles River Laboratories International by 2.7% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company’s stock worth $589,000 after purchasing an additional 102 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Charles River Laboratories International by 2.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company’s stock worth $763,000 after purchasing an additional 105 shares in the last quarter. Finally, Veracity Capital LLC boosted its stake in Charles River Laboratories International by 3.4% in the first quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company’s stock valued at $496,000 after buying an additional 107 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Joseph W. Laplume sold 400 shares of the firm’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $150.04, for a total transaction of $60,016.00. Following the completion of the transaction, the executive vice president directly owned 24,916 shares in the company, valued at $3,738,396.64. This trade represents a 1.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Citigroup raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and raised their price objective for the company from $150.00 to $200.00 in a research note on Wednesday, July 9th. JPMorgan Chase & Co. raised their price objective on Charles River Laboratories International from $145.00 to $160.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Cowen raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Wednesday, May 14th. TD Cowen raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 price objective on the stock in a research note on Wednesday, May 14th. Finally, Wall Street Zen raised Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research note on Saturday. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $175.69.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $152.69 on Wednesday. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $7.51 billion, a PE ratio of -114.80, a P/E/G ratio of 4.75 and a beta of 1.48. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $230.02. The stock has a 50-day moving average price of $156.11 and a two-hundred day moving average price of $149.02.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. During the same period last year, the company earned $2.80 earnings per share. The business’s quarterly revenue was up .6% on a year-over-year basis. Analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).